Shiba Inu’s community has grown increasingly anxious as lead developer Shytoshi Kusama continues his extended absence on X, where he last posted or interacted on May 13, 2026. Despite minimal updates from Kusama himself, low-level activity continues across the broader Shiba Inu ecosystem, with developers and community members maintaining momentum on multiple fronts.
Shiba Inu lead Shytoshi Kusama silent since May, ecosystem activity persists
Speculation over Kusama’s absence
Shytoshi Kusama, Shiba Inu’s principal figure and the public face of the project, has maintained a low online profile for several months. In September 2026, Kusama updated his X bio to the word “Polish” and changed his location to “Close.” These ambiguous modifications fueled speculation among followers about potential ongoing projects nearing completion, but Kusama has not provided clarity regarding whether these changes relate to Shiba Inu, his artificial intelligence endeavors, or another initiative.
Kusama’s social media silence comes at a pivotal time for the popular meme coin, whose developer base and online following are accustomed to regular updates and public engagement from the project lead.
Kusama’s last visible change on X, simply updating his bio to “Polish” and his location to “Close,” sparked community debate over whether major Shiba Inu developments are imminent.
The lack of official statements from Kusama has left many in the community looking for signals about the direction of the project and the status of ongoing developments.
Shibarium developments continue
Despite the absence of direct updates from Kusama, the Shiba Inu ecosystem has experienced ongoing development activity, particularly around its layer-2 network, Shibarium. The network, designed to reduce transaction costs and improve scalability for the Shiba Inu token and related assets, has undergone several technical updates in recent weeks.
Community member Mazrael reported on X in September 2026 that the Shibarium “reorg” issue, discussed in earlier months, has now been resolved according to developer Kaal Dhairya. The only remaining task is for the Decentralized Remote Procedure Call (DRPC) service to complete the same transition in the new environment.
Mazrael also stated that Shibarium remains in a rebuild phase. Nonetheless, the platform has incorporated new features and improvements, including the launch of CreateX, which enables developers to deploy contracts at identical addresses across multiple blockchains. The rollout of all 12 Safe v1.4.1 contracts at canonical addresses was completed via the Safe Singleton Factory.
Additionally, the x402 component is now fully operational on Shibarium, facilitating payments for AI agents using SHIB, TREAT, or wrapped BONE tokens.
Mini dictionary: Shibarium is Shiba Inu’s layer-2 blockchain solution built to improve transaction speeds and lower fees for users holding SHIB and related tokens. The platform aims to expand the utility of the Shiba Inu ecosystem beyond simple token transfers.
Infrastructure enhancements
The Shibarium Remote Procedure Call (RPC) listing was refreshed in the Ethereum-lists/chains registry, giving users updated technical details for establishing network connections. According to the latest updates, Chainlist also now provides these new connection parameters.
In September, Shiba Inu’s official website and the ShibaSwap page migrated to Cloudflare, with support for IPv6 added. This change moves the infrastructure away from its former hosting provider, enhancing online performance and security for users accessing core Shiba Inu services.
| Kusama activity on X | No posts/interactions since May 13, 2026 |
| Shibarium reorg | Solved; final step pending DRPC migration |
| CreateX deployment | Live on Shibarium |
| Safe v1.4.1 contracts | All 12 deployed via Safe Singleton Factory |
| x402 payments | Live; accepts SHIB, TREAT, wrapped BONE |
| Website/Swap migration | Moved to Cloudflare, IPv6 enabled |
Community developers, including Mazrael and Kaal Dhairya, have provided updates on Shibarium’s technical progress, confirming that despite leadership silence, the platform’s growth continues.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
U.S. non-farm payrolls surge by 165,000 in October, far exceeding expectations! Unemployment rate unexpectedly drops to 4.1%, December rate hike expectations intensify
In October, US non-farm payrolls increased by 165,000, which is 2.5 times the Wall Street median forecast of 65,000 and represents an exceptionally strong deviation of about 5 standard deviations, exceeding the upper limit of all institutional forecast ranges. The unemployment rate unexpectedly fell from 4.2% to 4.1%, while the market had expected it to remain unchanged; average hourly wages also accelerated year-on-year growth to 3.1%. Meanwhile, the previous two months' non-farm payrolls were revised upwards by a total of 84,000. Following the release of the data, the yield on 2-year US Treasury bonds rose by 7 basis points, and the pricing of the probability of a Fed rate hike in December climbed to 70%.
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion
The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.

Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight
Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.
